We are ONE team,
working towards ONE goal to

Detect Disease

ONE molecule at a time.

One in a
Few Billion

There are three billion letters, three billion nucleotides that make up our genome. Our proprietary technology has the ability to detect and quantify disease at single base-pair resolution. Our name speaks to this unique technology, and we are focused on applying it to various disease states to help more patients.

Moving Prenatal Screening and Oncology Testing Forward

Prenatal

We assess fetal risk for recessive conditions and aneuploidies from maternal blood.

UNITY Complete® includes a carrier screen as well as a single-gene (for recessive conditions) and aneuploidy NIPT and only requires a maternal blood draw at 9+ weeks to assess fetal risk.

Oncology

Northstar Select™ and Northstar Response™ are now available for commercial use.

Northstar Select™ helps determine the most appropriate first line therapy, and Northstar Response™ helps monitor if the therapy is working.

"BillionToOne's leadership values growth of the company's employees and equality among peers."

Aaron Aquino
Office Manager

Coupling Careers with Great Culture

What unites our team and drives us forward is one goal of making molecular testing more accurate, efficient, and accessible to all. This special group of bright and talented people is improving healthcare. If this appeals to you, consider joining us.

Leading with Passion and Purpose

Co-founders Oguzhan Atay, Ph.D., and David Tsao, Ph.D., and our team of engineers, scientists, and industry experts care deeply about every sample that comes into our lab.

News & Media

View All